FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Maravai LifeSciences Holdings, Inc. Stock AnalysisComprehensive stock analysis for Maravai LifeSciences Holdings, Inc. (MRVI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMRVI
MRVI
Maravai LifeSciences Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MRVI
Home🔹Stocks🔹Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc.

🇺🇸MRVI•NASDAQ

Maravai LifeSciences Holdings, Inc.

🇺🇸MRVI•NASDAQ
Market cap
$1.80B
Sentiment

Your view on MRVI

Mkt Cap
$1.80B
Sentiment
Your view
MRVI
Maravai LifeSciences Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MRVI
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Maravai LifeSciences Holdings, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Bernd Brust
Headquarters
10770 Wateridge Circle, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Bernd Brust
Headquarters
10770 Wateridge Circle, San Diego, CA, US
Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally.

The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.

The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology.

The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services.

The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Maravai LifeSciences Holdings, Inc., and the rating behind it. MRVI last traded at $6.53; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Maravai LifeSciences Holdings, Inc.. Starting points for Maravai LifeSciences Holdings, Inc.: EPS -$0.52, beta 0.60 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Maravai LifeSciences Holdings, Inc.. Maravai LifeSciences Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Maravai LifeSciences Holdings, Inc.. Trailing twelve-month EPS for Maravai LifeSciences Holdings, Inc. stands at -$0.52. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Maravai LifeSciences Holdings, Inc.. Maravai LifeSciences Holdings, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Maravai LifeSciences Holdings, Inc. valued side by side against its closest peers. Maravai LifeSciences Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Maravai LifeSciences Holdings, Inc., and how their positions are changing. At a $1.80B market value, institutional positions materially move Maravai LifeSciences Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Maravai LifeSciences Holdings, Inc. executives and directors. Shares of Maravai LifeSciences Holdings, Inc. have traded between $1.67 and $6.21 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Maravai LifeSciences Holdings, Inc.. Maravai LifeSciences Holdings, Inc. is a $1.80B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Maravai LifeSciences Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Maravai LifeSciences Holdings, Inc.. Coverage tracks Maravai LifeSciences Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • BCAX — Bicara Therapeutics Inc. Common Stock
  • DNA — Ginkgo Bioworks Holdings, Inc.
  • IOVA — Iovance Biotherapeutics, Inc.
  • KURA — Kura Oncology, Inc.
  • LENZ — LENZ Therapeutics, Inc.
  • PRME — Prime Medicine, Inc.
  • REPL — Replimune Group, Inc.
  • SEPN — Septerna, Inc.

More Biotechnology companies

  • FNCHQ — Finch Therapeutics Group, Inc.
  • FORU — ForU Holdings, Inc.
  • FPMI — FluoroPharma Medical, Inc.
  • FRNM — Freenome, Inc. Common stock
  • FRX.TO — Fennec Pharmaceuticals Inc.
  • FTH — Faeth Therapeutics, Inc.
  • FTRE — Fortrea Holdings Inc.
  • FULC — Fulcrum Therapeutics, Inc.
  • GALT — Galectin Therapeutics Inc.
  • GANX — Gain Therapeutics, Inc.
  • GBIM — GlobeImmune, Inc.
  • GBLX — GB Sciences, Inc.

ETFs holding Maravai LifeSciences Holdings, Inc.

  • FESC — First Eagle Small Cap Equity ETF (1.12%)
  • NIXT — Research Affiliates Deletions ETF (0.84%)
  • GNOM — Global X - Genomics & Biotechnology ETF (0.57%)

News

Latest Market News